A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PKU (SYNPHENY-3) - SYNB1934-CP-003

Synlogic Inc.0 个研究点目标入组 150 人2023年10月6日

适应症Phenylketonuria MedDRA version: 20.0Level: LLTClassification code: 10034873Term: Phenylketonuria (PKU) Class: 10010331 Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

概览

阶段: 1 期
干预措施: 未指定
疾病 / 适应症: Phenylketonuria
发起方: Synlogic Inc.
入组人数: 150
状态: 进行中（未招募）
最后更新: 去年

概览研究者入排标准结局指标相似试验

概览

简要总结

A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy an

注册库

who.int

开始日期

2023年10月6日

结束日期

2024年3月15日

最后更新

去年

研究类型

Interventional clinical trial of medicinal product

性别

All

研究者

发起方

Synlogic Inc.

入排标准

入选标准

•Age \= 18 years. Participants 12 to 17 years of age may be enrolled after the first 20 participants have completed the DEP, with approval of the DMC., Able and willing to voluntarily complete the informed consent process (adults; parents/guardians) or informed assent process (minors)., Diagnosis of PKU and failure to maintain recommended blood Phe levels on existing management (sapropterin, sepiapterin and/or Phe\-restricted diet), demonstrated by uncontrolled blood Phe level \> 360 µmol/L on current therapy any time during screening and uncontrolled blood Phe level \> 360 µmol/L on current therapy when taking the average of the 3 most recent Phe levels from the participant’s medical history (inclusive of any screening values). All screening values must be obtained more than 7 days apart, as determined by central or local laboratory., Females of childbearing potential must have a negative pregnancy test at screening and the end of DEP (in order to enter Part 2\) and RWP (in order to enter Part 3\) and be willing to have additional pregnancy tests during the study., Sexually active female participants of childbearing potential must be willing to use a highly effective method of contraception while participating in the study and for 2 weeks after the last dose., Stable diet including stable medical formula regimen (if used) for at least 1 month prior to screening., If using sapropterin or sepiapterin, must be on a stable dose for at least 3 months., Willing and able to continue current diet, sapropterin, sepiapterin and large neutral amino acids unchanged during screening, DEP, and RWP and to engage in all study activities.

排除标准

•Currently taking Palynziq® (pegvaliase\-pqpz) (within 1 month of screening)., Acute or chronic medical, surgical, psychiatric, or social condition or laboratory abnormality that may increase participant risk associated with study participation, compromise adherence to study procedures and requirements, and, in the judgment of the investigator, would make the participant inappropriate for enrollment., A known or suspected diagnosis of DNAJC12 deficiency, biopterin synthesis deficiency, or irritable bowel syndrome., Intolerance of or allergic reaction to E. coli Nissle or any of the ingredients in SYNB1934v1 or placebo formulations, or an allergy to cinnamon. Known intolerance to proton pump inhibitors and H2 blockers, since one or the other must be used., Currently taking or plans to take any type of systemic (e.g., oral or intravenous) antibiotic within 28 days prior to the first dose of IMP through final safety assessment in RWP, including planned surgery, hospitalizations, dental procedures, or interventional studies that are expected to require antibiotics. Exception: topical antibiotics are allowed., Pregnant, planning to become pregnant, or breastfeeding., Current participation in any other investigational drug study or use of any investigational agent within 30 days or 5 half\-lives (whichever is longer) prior to screening., Ever received gene therapy for treatment of PKU.